Tegoprubart: Expanding Islet Transplants to T1D and Kidney Disease
What’s Happening? A new Breakthrough T1D-funded clinical trial investigating Eledon Pharmeceuticals’ immunotherapy, tegoprubart, with islet cell transplants in people with type 1 diabetes (T1D) and chronic kidney disease (CKD) just launched! This is the first time people with T1D and reduced kidney function are eligible for an islet cell therapy clinical trial—and the first person […]
Islet Cell Therapies Take the Stage at Public Workshop
Islet cell therapies for type 1 diabetes (T1D) are in the works. In clinical trials, people are coming off external insulin—and experiencing healthy blood sugar levels. Researchers and clinicians are working hard behind the scenes to advance next-generation manufactured islet cell therapies as scalable cures. The momentum is real—and it’s more important than ever to […]
New Publication: Sana’s Gene-Edited Islets Continue to Make Insulin
What’s Happening? A new publication in The New England Journal of Medicine provides more detail about the first person with type 1 diabetes (T1D) treated with Sana Biotechnology’s gene-edited islets. This person is still making insulin 14+ months after their islet transplant—without immunosuppressants! What to Know About Sana’s Gene-Edited Islets Sana’s novel cell therapy approach […]
A Roadmap to Accelerate Cell Therapies into Clinical Trials
What’s Happening? A new Breakthrough T1D publication lays out the first clear preclinical testing and manufacturing roadmap for getting islet cell therapies for type 1 diabetes (T1D) into human clinical trials faster. What is This Publication About? Before any new therapy—including islet cell therapies for T1D—can move into in-human clinical trials, they need to go […]
Cell Therapy Clinical Trials: Breaking Down the Science
Breakthrough T1D is here to answer all of your questions about islet cell therapies, from the research lab to real-world treatments.
ADA 2026 Recap: Days 3 and 4
ADA’s 86th Scientific Sessions This event is one of the largest diabetes conferences in the world, bringing together over 11,000 attendees to share and learn about cutting-edge research and advancements toward cures. Each year, Breakthrough T1D-funded researchers highlight their work, demonstrating the progress we’re making toward achieving our mission. Leading experts will present over 100 […]
All 12 Clinical Trial Participants Off External Insulin: New Data on Tegoprubart Continues to Impress
New data from a Breakthrough T1D–funded islet cell transplant trial shows all 12 participants are off external insulin using tegoprubart.
ADA 2026 Recap: Days 1 and 2
ADA’s 86th Scientific Sessions This event is one of the largest diabetes conferences in the world, bringing together over 11,000 attendees to share and learn about cutting-edge research and advancements toward cures. Each year, Breakthrough T1D-funded researchers highlight their work, demonstrating the progress we’re making toward achieving our mission. Leading experts will present over 100 […]
International Experts Advance Clinical Adoption of Islet Cell Therapies at Breakthrough T1D HQ
Islet cell therapies for type 1 diabetes (T1D) replace destroyed insulin-producing beta cells with functional cells that allow the body to make insulin again. To ensure there are enough islet cells for everyone with T1D who wants them, Breakthrough T1D is prioritizing manufactured cell therapies, which can be made in large quantities in a laboratory, […]
An Interview with Vertex
It’s an exciting time for type 1 diabetes (T1D) research. Nearly every day, we’re seeing incredible progress across each area of Breakthrough T1D’s research portfolio to cure, prevent, and treat T1D and its complications. One area in particular is making headlines: Cell therapies. In T1D, the immune system destroys the beta cells in the pancreas, which produce insulin. Cell therapies aim to replace […]
